These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 92960)

  • 1. High-affinity dopamine receptors solubilized from dog striatum [proceedings].
    Gorissen H; Laduron P
    Arch Int Physiol Biochim; 1979 May; 87(2):414-5. PubMed ID: 92960
    [No Abstract]   [Full Text] [Related]  

  • 2. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA; Marsh CL
    Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are striatal [3H]spiperone radioreceptor assays indicative of multiple dopamine receptor interactions?
    Clements-Jewery S; Robson PA
    Neuropharmacology; 1981 Dec; 20(12B):1295-8. PubMed ID: 7322304
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of (3H)-terguride and (3H)-spiperone binding to dopamine receptors in the rat striatum.
    Valchár M; Dobrovský K; Krejcí I; Dlabac A
    Act Nerv Super (Praha); 1989 Apr; 31(1):77-9. PubMed ID: 2675526
    [No Abstract]   [Full Text] [Related]  

  • 5. Cerebellar and striatal dopamine receptors: effects of reeler and weaver murine mutations.
    Panagopoulos NT; Matsokis NA; Valcana T
    J Neurosci Res; 1993 Aug; 35(5):499-506. PubMed ID: 8377223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of the apparent affinity of the striatal dopamine receptors for the radioligand[3H]spiperone [( 3H]spiroperidol).
    Hruska RE
    J Neurosci Res; 1984; 12(4):571-81. PubMed ID: 6512888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of [3H]spiperone with rat striatal dopamine D-2 receptors: kinetic evidence for antagonist-induced formation of ternary complex.
    Chatterjee TK; Scott CE; Vazquez DM; Bhatnagar RK
    Mol Pharmacol; 1988 Apr; 33(4):402-13. PubMed ID: 3357484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relation between brain D2-dopamine receptors and 3H-spiperone binding sites of intact lymphocytes].
    Noguchi-kuno SA; Nakata C; Nishitani H
    Rinsho Shinkeigaku; 1983 Sep; 23(9):814-8. PubMed ID: 6232031
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine agonist high-affinity state in solubilized D2 receptors in striatum, but not in anterior pituitary.
    Dumbrille-Ross A; Seeman P
    Biochem Pharmacol; 1987 Jul; 36(13):2095-9. PubMed ID: 2955789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists.
    Martin GE; Williams M; Haubrich DR
    J Pharmacol Exp Ther; 1982 Nov; 223(2):298-304. PubMed ID: 6813451
    [No Abstract]   [Full Text] [Related]  

  • 11. Similarities and dissimilarities between dopamine and neuroleptic receptors: further evidence for type 1 and type 2 dopamine receptors in the CNS.
    Spano PF; Memo M; Govoni S; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 24():113-21. PubMed ID: 6105769
    [No Abstract]   [Full Text] [Related]  

  • 12. Purification of the D-2 dopamine receptor from bovine striatum.
    Elazar Z; Kanety H; David C; Fuchs S
    Biochem Biophys Res Commun; 1988 Oct; 156(1):602-9. PubMed ID: 2972288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of solubilized dopamine receptors from spirodecanone binding sites in rat striatum.
    Gorissen H; Ilien B; Aerts G; Laduron P
    FEBS Lett; 1980 Nov; 121(1):133-8. PubMed ID: 6161839
    [No Abstract]   [Full Text] [Related]  

  • 14. Dopamine receptor: isolation, purification, and regulation.
    Clement-Cormier YC
    Adv Biochem Psychopharmacol; 1980; 21():159-67. PubMed ID: 7376969
    [No Abstract]   [Full Text] [Related]  

  • 15. D-2 dopamine receptors in aging mouse striatum: determination of high- and low-affinity agonist binding sites.
    Severson JA; Randall PK
    J Pharmacol Exp Ther; 1985 May; 233(2):361-8. PubMed ID: 3158731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of multiple receptors for dopamine.
    Spano PF; Memo M; Stefanini E; Fresia P; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 21():243-51. PubMed ID: 7376971
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
    Bennett JP; Wooten GF
    Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solubilization of neuroleptic/dopamine receptors of human brain striatum.
    Davis A; Madras B; Seeman P
    Eur J Pharmacol; 1981 Mar; 70(3):321-9. PubMed ID: 6112153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential inhibitory effects of ascorbic acid on the binding of dopamine agonists and antagonists to neostriatal membrane preparations: correlations with behavioral effects.
    Heikkila RE; Cabbat FS; Manzino L
    Res Commun Chem Pathol Pharmacol; 1981 Dec; 34(3):409-21. PubMed ID: 7323442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascorbic acid, redox cycling, lipid peroxidation, and the binding of dopamine receptor antagonists.
    Heikkila RE; Manzino L
    Ann N Y Acad Sci; 1987; 498():63-76. PubMed ID: 3476003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.